• 1\. Subject has provided informed consent/assent prior to initiation of any study specific activities/procedures.

• 2\. Female age ≥ 18 years at the time of informed consent. 3. Histologically confirmed diagnosis of breast cancer. 4. Disease stage: unresectable or metastatic stage IV breast cancer. 5. Candidate for palliative SBRT independent from study enrollment 6. Measurable disease, defined as at least 1 visceral or nodal/soft tissue breast cancer lesion that can be accurately and serially measured in at least 1 dimension and for which the longest diameter is ≥ 10 mm as measured by Computer Tomography scan or Magnetic Resonance Imaging. Lymph nodes must measure ≥ 15 mm in their short axis to be considered measurable by Computer Tomography scan or Magnetic Resonance Imaging or Positron Emission Tomography-CT.

• 7\. If subject received major surgery, must have recovered adequately from toxicity and/or complications from the intervention prior to enrollment.

• 8\. Subject must have received two prior lines of therapy and include a taxane in the adjuvant/neoadjuvant or metastatic setting.

⁃ Triple negative breast cancer patients must have received two lines of chemotherapy in the metastatic setting.

⁃ ER+/ PR+, ER-/PR+, and ER+/PR- must have received prior Cyclin Dependent Kinase 4/6 Inhibitor in combination with Aromatase Inhibitor or fulvestrant. However, ER+/Her2 overexpressed patients are not required to have received CDK 4/6 inhibitor.

⁃ Her2 overexpressed breast cancer must have had prior trastuzumab/per (in the neoadjuvant/adjuvant or metastatic setting, and prior Ado-trastuzumab TDM1 therapy.

‣ 9\. Adequate organ function determined within 14 days prior to enrollment, defined as follows:

∙ Absolute neutrophil (ANC) \>1.5 x 109/L

∙ Platelet count\>50 x 109/L

∙ Hemoglobin\>8 g/dL

∙ Serum creatinine \<2.0 x upper limit of normal

∙ Serum bilirubin \< 2.0 x ULN OR direct bilirubin ≤ ULN for a subject with total bilirubin level \> 2.0 x ULN

∙ Aspartate aminotransferase (AST) \<2.5 x ULN OR \<5 x ULN for subject with liver metastases

∙ Alanine aminotransferase (ALT) \<2.5 x ULN OR \<5 x ULN for subject with liver metastases

∙ International normalization ratio (INR) or prothrombin time (PT) \<1.5 x ULN unless the subject is receiving anticoagulant therapy as long as PT and partial thromboplastin time (PTT)/activated PTT (aPTT) is within therapeutic range of intended use of anticoagulants

∙ Lactate dehydrogenase (LDH) levels ≤ 1.5 X upper limit of normal (ULN) within 28 days prior to enrollment

∙ Female subject of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to enrollment. If the urine pregnancy test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

∙ ECOG performance status of 0, 1 or 2.